Searchable abstracts of presentations at key conferences in endocrinology

ea0038p400 | Steroids | SFEBES2015

Rapid equilibriation of cortisol between the free and total plasma pools

Anderson Anna , Cairns Carolynn , Stimson Roland , Andrew Ruth , Mohd-Shukri Nor , Reynolds Rebecca , Walker Brian

Background: Using a deuterated tracer (D4-cortisol) to measure cortisol regeneration from cortisone in vivo we have quantified tissue-specific 11βHSD1 activity in health and disease, and acute regulation eg by insulin. These studies relied on tracer enrichment in the total plasma cortisol pool, assuming rapid equilibration between free and protein-bound pools. Slower equilibration would result in underestimation of enzyme activity, and has implications for the co...

ea0036oc4.7 | Oral Communications 4 | BSPED2014

Pitfalls in the diagnosis of neonatal adrenal insufficiency

Irvine Vanessa , Davis Nikki , Walker Jo , Wickramasuriya Nalin , Cook Paul , Armston Annie , Davies Justin

Introduction: Adrenal insufficiency is rare in the neonatal period and if unrecognised may cause life-threatening circulatory collapse. The initial investigations taken at the time of presentation, and prior to the institution of hydrocortisone, are a key step in the diagnostic pathway, and aid the clinician to distinguish adrenal insufficiency from mineralocorticoid resistance or renal tubulopathy. A cortisol measurement at the time of illness is useful to evaluate the adrena...

ea0031oc1.5 | Young Endocrinologists prize session | SFEBES2013

Inhibition of 5α-reductase type 1 with dutasteride impairs insulin sensitivity

Upreti Rita , Hughes Katherine , Gray Calum , Minns Fiona , Marshall Ian , Stewart Laurence , Walker Brian , Andrew Ruth

5α-Reductase (5αR) inhibitors decrease prostatic dihydrotestosterone in benign prostatic hyperplasia (BPH) treatment; finasteride inhibits 5αR type 2, while dutasteride inhibits 5αR1 and 2. 5αRs, especially 5αR1, are also expressed in metabolic tissues regulating actions of androgens and other substrates, including glucocorticoids.Hypothesis: 5αR1 inhibition with dutasteride induces metabolic dyshomeostasis.<p class...

ea0031oc4.6 | Obesity, metabolism and bone | SFEBES2013

Transgenic disruption of 5α-reductase 1 increases susceptibility to liver fibrosis

Livingstone Dawn , Rees Georgina , Weldin Benjamin , MacFarlane David , Walker Brian , Andrew Ruth

5α-Reductase 1 (5aR1) catalyses A-ring reduction of glucocorticoids and androgens, predominantly in liver and modulates steroid hormone action. We previously demonstrated transgenic disruption of 5aR1 predisposes mice to developing fatty liver. Here we tested whether 5aR1 disruption increases susceptibility to the development of liver injury, using the carbon tetrachloride induced liver fibrosis model.Male 5aR1−/− (KO) mice and wild-type...

ea0030oc5.3 | Oral Communications 5 | BSPED2012

A comparison of patient's preferences for attributes of GH delivery devices: children starting versus children established on GH treatment

Yaw Stephanie How , Mushtaq Talat , Alvi N S , Walker Jenny , Whitehead Amanda

Background: Several devices are available for the administration of recombinant GH. A prospective study was undertaken to look at those attributes of GH delivery device most important to patients when making their choice.Objectives: i) To understand which features of a GH device are considered most important to patients when choosing a device. ii) Comparison of patient’s device preferences at start of GH treatment and after 2 years of treatment. iii...

ea0029p1427 | Pituitary Clinical | ICEECE2012

Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment

Howlett T. , Willis D. , Walker G. , Wass J. , Trainer P. , UK National Acromegaly Register Investigators

UK National Acromegaly Register collects data on real-life clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control on medical treatment (Rx) with somatostatin analogs (SMS) and dopamine agonists (DA).Methods: All GH records (basal, profile or GTT) in database were correlated with IGF1, Rx, surgery (TSS) and radiotherapy (RT), then processed to derive summary data for each patient and each course of Rx. GH considere...

ea0028yep1.2 | Young endocrinologists' prize lectures | SFEBES2012

Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease

Stimson Roland , Andrew Ruth , Shukri Nor , Johnstone Alexandra , Hayes Peter , Olsson Tommy , Reynolds Rebecca , Walker Brian

Tissue cortisol levels are amplified by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). In mice, transgenic overexpression of 11β-HSD1 causes the metabolic syndrome, consequently 11β-HSD1 inhibitors are a promising therapeutic target. However, determining the importance of 11β-HSD1 in humans has proved more complicated, in part due to difficulty quantifying in vivo activity. We hypothesized that cortisol regeneration by 11β-H...

ea0028oc5.8 | Growth, tumours and pituitary | SFEBES2012

Control of GH and IGF1 in acromegaly in the UK: Responses to medical treatment

Howlett Trevor , Willis Debbie , Walker Gillian , Wass John AH , Trainer Peter , UK National Acromegaly Register Investigators

UK National Acromegaly Register collects data on routine clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control & responses to medical treatment (Rx) with somatostatin analogs (SMS) & dopamine agonists (DA). Methods: Under program control, GH records (basal, profile or GTT) were correlated with IGF1, tumour size, Rx, surgery (TSS) & radiotherapy (RT) in the database, then processed in Excel to derive summary data for each pa...

ea0028p174 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2012

Reducing glucocorticoid action improves hyperinsulinaemia but not insulin-sensitive glucose or fatty acid turnover in patients with type 2 diabetes with and without fatty liver

Macfarlane David , Raubenheimer Peter , Bastin Mark , Marshall Ian , Andrew Ruth , Walker Brian

Background & Aims: Observational studies implicate glucocorticoid excess, principally due to altered steroid metabolism in target tissues, in both the insulin resistance and liver fat accumulation that accompanies type 2 diabetes. To test the contribution of glucocorticoid signalling to metabolic dysfunction we blocked cortisol secretion (with metyrapone) and action (with the GR antagonist mifepristone) simultaneously in men with type 2 diabetes ± fatty liver.<p c...

ea0028p288 | Reproduction | SFEBES2012

Genetic variants in CYP19 associated with increased aromatase activity are not associated with male hypogonadism in type 2 diabetes

Gibb Fraser , Walker Brian , Reynolds Rebecca , Strachan Mark , Beckett Geoff , Price Jackie

Background: Testosterone deficiency is common in obesity and in type 2 diabetes mellitus. It is hypothesised that the expanded adipose pool, which is the major source of aromatase in men, depletes testosterone levels by excess conversion to estradiol. Individuals with either the GG rs2470152 polymorphism in intron 1 or a high number of TTTA repeats in intron 4 of CYP19 are known to have greater aromatase activity with demonstrable effects upon plasma estradiol and osteoporosis...